

seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: June 10, 1997.

**Joseph A. Levitt,**

*Deputy Director for Regulations Policy, Center for Devices and Radiological Health.*

[FR Doc. 97-17971 Filed 7-9-97; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 97M-0253]

#### Medispec, Ltd.; Premarket Approval of Econolith™ Extracorporeal Shock Wave Lithotripter

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing its approval of the application by Medispec Ltd., Rockville, MD, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the Medispec Ltd., Econolith™ Lithotripter. FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of April 7, 1997, of the approval of the application.

**DATES:** Petitions for administrative review by August 11, 1997.

**ADDRESSES:** Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

**FOR FURTHER INFORMATION CONTACT:** Russell P. Pagano, Center for Devices and Radiological Health (HFZ-472), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-2194.

**SUPPLEMENTARY INFORMATION:** On December 26, 1995, Medispec Ltd., Rockville, MD, 20850, submitted to CDRH an application for premarket approval of the Econolith™ Lithotripter. The device is an extracorporeal shockwave lithotripter and is indicated for use in the noninvasive fragmentation of upper

urinary tract stones between 5 and 20 millimeters in size.

In accordance with the provisions of section 515(c)(2) of the act (21 U.S.C. 360e(c)(2)) as amended by the Safe Medical Devices Act of 1990, this premarket approval application (PMA) was not referred to the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee, an FDA advisory committee, for review and recommendation because the information in the PMA substantially duplicates information previously reviewed by this panel.

On April 7, 1997, CDRH approved the application by a letter to the applicant from the Deputy Director, Clinical and Review Policy, the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

#### Opportunity for Administrative Review

Section 515(d)(3) of the act authorizes any interested person to petition, under section 515(g) of the act, for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under 21 CFR part 12 of FDA's administrative practices and procedures regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under 21 CFR 10.33(b). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the **Federal Register**. If FDA grants the petition, the notice will state the issue to be reviewed, the form of the review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before August 11, 1997 file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information,

identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: June 10, 1997.

**Joseph A. Levitt,**

*Deputy Director for Regulations Policy, Center for Devices and Radiological Health.*

[FR Doc. 97-17973 Filed 7-9-97; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 97M-0166]

#### Johnson and Johnson Interventional Systems Co.; Premarket Approval of PALMAZ-SCHATZ™ Balloon-Expandable Stent

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing its approval of the application by Johnson and Johnson Interventional Systems Co., Warren, NJ, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of PALMAZ-SCHATZ™ Balloon-Expandable Stent. After reviewing the recommendation of the Circulatory System Devices Panel, FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of August 2, 1994, of the approval of the application. In addition, the PALMAZ-SCHATZ™ Balloon-Expandable Stent requires tracking under the act as amended by the Safe Medical Devices Act of 1990.

**DATES:** Petitions for administrative review by August 11, 1997.

**ADDRESSES:** Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

**FOR FURTHER INFORMATION CONTACT:** Bram D. Zuckerman, Center for Devices and Radiological Health (HFZ-450),